本文選題：羧基麥芽糖鐵　切入點：靜脈鐵劑　出處：《中國新藥雜志》2017年09期

【摘要】：缺鐵性貧血(iron deficiency anemia,IDA)是目前全球最常見的營養(yǎng)素缺乏疾病之一,其治療藥物主要以鐵劑為主,口服鐵劑應(yīng)用較早、價廉方便,但效果不理想。靜脈鐵劑的出現(xiàn)彌補了口服鐵劑吸收差、起效慢和不良反應(yīng)大的不足。近年來新型靜脈鐵劑不斷出現(xiàn),羧基麥芽糖鐵能夠滿足臨床大劑量快速給藥的需求,市場前景廣闊,是優(yōu)點最突出的新型靜脈鐵劑。文章概括了羧基麥芽糖鐵的基本理化信息、合成方法、代謝機制、臨床研究、國際銷售以及國內(nèi)注冊等情況,對羧基麥芽糖鐵在國內(nèi)的研究開發(fā)和推廣提供了參考。
[Abstract]:Iron deficiency anemia IDA is one of the most common nutrition deficiency diseases in the world at present. Its therapeutic drugs are mainly iron and iron, oral iron is used earlier, cheap and convenient, but the effect is not satisfactory.The presence of intravenous iron makes up for the poor absorption, slow onset and large adverse reactions of oral iron.In recent years, a new type of intravenous iron has been developed. Carboxymaltose iron can meet the needs of high dose and fast delivery in clinic. It has a broad market prospect and is the most outstanding new type of intravenous iron.In this paper, the basic physical and chemical information, synthetic method, metabolic mechanism, clinical research, international sales and domestic registration of carboxymaltose iron are summarized, which provides a reference for the research and development of carboxymaltose iron in China.
【作者單位】： 中國藥科大學(xué)理學(xué)院;江蘇神龍藥業(yè)有限公司;
【基金】：江蘇省“創(chuàng)新團隊計劃”項目(2013-043) 江蘇省“六大高峰人才”項目(2013-SWYY-009)
【分類號】：R259

【相似文獻】

相關(guān)期刊論文 前1條

1 沈建明;鄧妍妍;田少江;王黎萍;李駿峰;;大黃減輕維持性血液透析患者靜脈鐵劑誘導(dǎo)的氧化應(yīng)激和微炎癥反應(yīng)[J];安徽醫(yī)藥;2010年12期

，

本文編號：1721534